title: Expression of cancer testis genes in human brain tumors.
abstract: Cancer-testis (CT) genes are expressed in a variety of human cancers but not in normal tissues, except for testis tissue, and represent promising targets for immunotherapeutic and gene therapeutic approaches. Because little is known about their composite expression in human brain tumors, we investigated the expression of seven CT genes (MAGE-3, NY-ESO-1, HOM-MEL-40/SSX-2, SSX-1, SSX-4,HOM-TES-14/SCP-1, and HOM-TES-85) in 88 human brain tumor specimens. Meningiomas expressed only HOM-TES-14/SCP-1 (18% of meningiomas were HOM-TES-14/SCP-1 positive) and did not express any other CT genes. One ependymoma was negative for all CT genes tested. SSX-4 was the only CT gene expressed in oligodendrogliomas (2 of 5 cases), and it was also expressed in oligoastrocytomas (3 of 4 cases) and astrocytomas (10 of 37 cases). Astrocytomas were most frequently positive for HOM-TES-14/SCP-1 (40%) and SSX-4 (27%), followed by HOM-TES-85 (13%), SSX-2 (11%), and MAGE-3 (7%). Whereas MAGE-3 was detected only in grade IV astrocytomas, the expression of the other CT genes showed no clear correlation with histological grade. Of 39 astrocytomas, 60% expressed at least one CT gene, 21% expressed two CT genes, and 8% coexpressed three CT genes of the seven CT genes investigated. We conclude that a majority of oligoastrocytomas and astrocytomas might be amenable to specific immunotherapeutic interventions. However, the identification of additional tu-mor-specific antigens with a frequent expression in gliomas is warranted to allow for the development of widely applicable polyvalent glioma vaccines.
authors.affiliation: Department of Medicine, Saarland University Medical School, Homburg, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Sahin
authors.forename: M
authors.initials: M
authors.lastname: Koslowski
authors.forename: O
authors.initials: O
authors.lastname: Türeci
authors.forename: T
authors.initials: T
authors.lastname: Eberle
authors.forename: C
authors.initials: C
authors.lastname: Zwick
authors.forename: B
authors.initials: B
authors.lastname: Romeike
authors.forename: J R
authors.initials: JR
authors.lastname: Moringlane
authors.forename: K
authors.initials: K
authors.lastname: Schwechheimer
authors.forename: W
authors.initials: W
authors.lastname: Feiden
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
mesh_terms: D000951:Antigens, Neoplasm / Q000096:biosynthesis; D001254:Astrocytoma / Q000378:metabolism / Q000473:pathology; D001932:Brain Neoplasms / Q000378:metabolism*; D018076:DNA, Complementary / Q000378:metabolism; D004806:Ependymoma / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008565:Membrane Proteins; D008579:Meningioma / Q000378:metabolism; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009837:Oligodendroglioma / Q000378:metabolism; D014176:Protein Biosynthesis; D012097:Repressor Proteins / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013736:Testicular Neoplasms / Q000378:metabolism*; D013737:Testis / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D018076:DNA, Complementary; C072013:MAGEA3 protein, human; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D012097:Repressor Proteins; C093962:synovial sarcoma X breakpoint proteins